In a prospective cohort of 100 stage II–III HR+/HER2- BC patients treated with 3 months of anastrozole before surgery, Reinert et al. did not find any ESR1 mutation in the 23 surgical samples of endocrine-resistant tumors, defined as having a PEPI score ≥ 4- [80]. Here, ESR1 is linked to breast cancer.